Video Lectures from ACT China III 2013
PUBLISHED: 2014-03-06   2236 total views, 2 today

Over the course of the 3-day ACT China III Workshop, a global faculty of experts addressed the current issues and challenges in carrying out Phase I, II and III clinical trials through a series of lectures, discussions, and workshops. We believe that the curriculum – covering ethics, preclinical studies, clinical trial design and conduct, statistics and regulatory considerations – will help transform oncology research in China for the benefit of cancer patients in China and around the world.

11.22pm

1. Welcom and introduction

http://pub.smvp.cn/publishing/flash/563524620097940927_386922041666070322_386922041666070307/player.swf

2. the principal investigator's responsibilities in conducting biomarker driven clinical trials

Richard L. Schilsky

http://pub.smvp.cn/publishing/flash/563526217825775048_386922041666070322_386922041666070307/player.swf

3. Phase I biomarker driven clinical trials:objectives,design,endpoints

Lillian L.Siu

http://pub.smvp.cn/publishing/flash/563525526336040388_386922041666070322_386922041666070307/player.swf

4. Phase I trials of targeted agent combinations

Jin Li

http://pub.smvp.cn/publishing/flash/563523821234023861_386922041666070322_386922041666070307/player.swf

5. Pharmacokinetics, drug-target interactions, and identifying adverse events in phase I biomarker driven clinical trials

Lillian L.Siu

http://pub.smvp.cn/publishing/flash/563524362399903163_386922041666070322_386922041666070307/player.swf

6. Panel discussion:Phase I biomarker driven clinical trials

http://pub.smvp.cn/publishing/flash/563538518612110830_386922041666070322_386922041666070307/player.swf


11.23am

1. Development and validation of biomarkers as clinical tests

Lillian L.Siu

http://pub.smvp.cn/publishing/flash/563536684661074160_386922041666070322_386922041666070307/player.swf

2. Biomarker-driven PHASE II clinical trials

Richard L. Schilsky

http://pub.smvp.cn/publishing/flash/563538016100937193_386922041666070322_386922041666070307/player.swf

3. Adaptive design and biomarker-based Phase I, Phase II trials

J. Jack Lee

http://pub.smvp.cn/publishing/flash/563535585149447651_386922041666070322_386922041666070307/player.swf

4. Do we need Phase II trials in the biomarker driven study era?

Yi-Long Wu

http://pub.smvp.cn/publishing/flash/563537964561328373_386922041666070322_386922041666070307/player.swf

5. Panel discussion: Use of Phase II clinical trials in the era of biomarker driven research

http://pub.smvp.cn/publishing/flash/563535048278535647_386922041666070322_386922041666070307/player.swf


11.23pm

1. Statistical considerations for Phase III biomarker driven trials, interim analusis, and data monitoring

J. Jack Lee

http://pub.smvp.cn/publishing/flash/563851772051844605_386922041666070322_386922041666070307/player.swf

2. Panel discussion 1

http://pub.smvp.cn/publishing/flash/563851024727533737_386922041666070322_386922041666070307/player.swf

3. Panel discussion 2

http://pub.smvp.cn/publishing/flash/563850316057931256_386922041666070322_386922041666070307/player.swf


11.24am

1. Disscus1

http://pub.smvp.cn/publishing/flash/563859636136963344_386922041666070322_386922041666070307/player.swf 

2. Disscus2

http://pub.smvp.cn/publishing/flash/563858373416577215_386922041666070322_386922041666070307/player.swf

3. Opportunities and challenges in combining targeted therapies for breast cancer

Bi-yun Wang

http://pub.smvp.cn/publishing/flash/563857200890505399_386922041666070322_386922041666070307/player.swf

4. A multi center, randomized, phase II trial of MLN0128 versus placebo in 3rd line treatment of advanced NSCLC with wild-type EGFR/ALK

Qiang Nie

http://pub.smvp.cn/publishing/flash/563860207367613716_386922041666070322_386922041666070307/player.swf

5. Phase I study of ipilimumab in patients with advanced nasopharyngeal cancer

Jun-ning Cao

http://pub.smvp.cn/publishing/flash/563860099993430211_386922041666070322_386922041666070307/player.swf

6. Phase I clinical trial of MLN0128 combined with bevacizumab in solid tumors

Ji-fang Kong

http://pub.smvp.cn/publishing/flash/563859464338271500_386922041666070322_386922041666070307/player.swf

7. Randomized controlled phase II trial: efficiedcy and safety of MLN0128 in advanced gastric cancer

Hao Zhang

http://pub.smvp.cn/publishing/flash/563858798618340616_386922041666070322_386922041666070307/player.swf

8. Closing remarks

http://pub.smvp.cn/publishing/flash/563856857293122820_386922041666070322_386922041666070307/player.swf

 


Copyright © 1998 - 2021 Chinese Society of Clinical Oncology(CSCO). All Rights Reserved

京公网安备 11010502031031号

Contact Us

EMAIL:office@csco.org.cn

international@csco.org.cn

Phone:86(10)67726451 (Beijing)

86(25)84547290 (Nanjing)